Medical Information Notice
This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or qualified healthcare provider. Read full disclaimer
Entacapone
Quick Facts
- Generic Name
- Entacapone
- Brand Names
- Comtan
- Drug Class
- COMT inhibitor
- FDA Approved
- 1999
How It Works
Entacapone is a selective, reversible inhibitor of catechol-O-methyltransferase (COMT), an enzyme that breaks down levodopa in the peripheral bloodstream before it can reach the brain. By blocking peripheral COMT, entacapone extends the plasma half-life and bioavailability of each levodopa dose, providing more consistent dopamine levels and reducing the wearing-off phenomenon. It has no benefit when taken without levodopa.
What to Expect as a Patient
Entacapone is added to your existing levodopa regimen — you take one 200mg tablet with every dose of levodopa/carbidopa. Most people notice a smoother, longer-lasting effect from each levodopa dose within the first few days. Your urine will turn brownish-orange; this is harmless and expected. Diarrhea is the most common bothersome side effect, typically developing within the first 4-12 weeks. If diarrhea becomes persistent or severe, contact your doctor. Because entacapone increases the effectiveness of levodopa, you may experience increased dyskinesia initially — your doctor may reduce your levodopa dose by 10-25% to compensate.
Typical Dosing
200mg with each levodopa dose. Maximum 8 doses (1600mg) per day. Also available as Stalevo (fixed combination of carbidopa/levodopa/entacapone).
Dosing is individualized by the prescribing physician. The information above is for general reference only.
Common Side Effects
- Diarrhea
- Urine discoloration (brownish-orange — harmless)
- Nausea
- Dyskinesia (due to increased levodopa effect)
- Abdominal pain
Serious Side Effects
Seek medical attention immediately if you experience any of the following:
- Rhabdomyolysis (rare)
- Severe persistent diarrhea
Contraindications
- Concurrent nonselective MAO inhibitors
- Known hypersensitivity
Food Interactions
Always taken together with levodopa/carbidopa. Does not have any PD benefit when taken alone. The brownish-orange urine discoloration is harmless and expected.
Drug Interactions
The following interactions have been documented with Entacapone. Always inform your healthcare provider about all medications you are taking.
Entacapone extends levodopa duration by inhibiting COMT. This is the intended therapeutic combination.
Clinical effects: May increase dyskinesia and other levodopa side effects due to increased bioavailability.
Management: Standard adjunct therapy. Levodopa dose may need reduction by 10-25% when adding entacapone.
Two COMT inhibitors should not be used concurrently as there is no additional benefit and increased hepatotoxicity risk with tolcapone.
Clinical effects: Excessive COMT inhibition, increased risk of diarrhea, hepatotoxicity (tolcapone), and levodopa-related adverse effects.
Management: Use only one COMT inhibitor at a time. Tolcapone is reserved for patients who fail entacapone or opicapone. Switch directly without overlap.
Two COMT inhibitors provide no additional benefit over one and increase the risk of excessive COMT inhibition and levodopa-related side effects.
Clinical effects: Excessive COMT inhibition, increased risk of diarrhea, dyskinesia, nausea, and orthostatic hypotension.
Management: Use only one COMT inhibitor. Opicapone may be preferred due to once-daily dosing. Switch directly without overlap.
How Entacapone Compares to Alternatives
Entacapone is one of three COMT inhibitors available (along with opicapone and tolcapone). Compared to opicapone: entacapone must be taken with each levodopa dose (up to 8 times daily) while opicapone is taken once daily at bedtime. A 2023 real-world comparison found entacapone resulted in 18.5% more neurology visits than opicapone over 6 months, suggesting inferior symptom control. However, entacapone does not carry the hepatotoxicity risk seen with tolcapone and requires no liver monitoring. Compared to tolcapone: entacapone is much safer (no hepatotoxicity risk) but less potent, reducing off-time by approximately 1 hour/day vs. 2 hours/day for tolcapone. For most patients, entacapone or opicapone is preferred over tolcapone.
When Is Entacapone Used by Disease Stage?
Not used in early PD: Entacapone is only relevant when a patient is taking levodopa and experiencing wearing-off motor fluctuations. This typically begins in mid-stage PD (Stages 2.5-3), when the effect of each levodopa dose no longer lasts until the next scheduled dose. Mid-stage PD (Stage 2.5-3): First-line adjunct when wearing off develops. Often the first medication added to levodopa. Advanced PD (Stages 4-5): Continued as part of multi-drug regimens. Many patients at this stage switch to opicapone for once-daily convenience or transition to advanced therapies (Duopa, DBS).
Additional Notes
Only useful as adjunct to levodopa. Available as combination pill with levodopa/carbidopa (Stalevo). Clinical trials show it reduces off-time by approximately 0.8-1.0 hours per day. Unlike tolcapone, entacapone does not carry a risk of liver toxicity and requires no liver monitoring. Diarrhea is the most common reason for discontinuation.
Clinical Perspective
Entacapone is the workhorse COMT inhibitor — not the most potent, not the most convenient, but the safest. Its 25-year safety track record is its greatest asset. The Stalevo combination tablet (carbidopa/levodopa/entacapone) simplified dosing when it launched, though the multiple dose strengths can be confusing. In practice, many neurologists are now starting new patients on opicapone instead because of its once-daily dosing advantage and evidence of fewer neurology visits. However, entacapone remains widely prescribed, especially where cost is a consideration, and its generic availability makes it the most affordable COMT inhibitor.
This perspective is based on published clinical evidence and guidelines. Individual treatment decisions should always be made with your neurologist.
Sources
- [1]Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson disease patients. Ann Neurol. 1997;42(5):747-755
- [2]Brooks DJ, Sagar H, UK-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry. 2003;74(8):1071-1079
- [3]Ferreira JJ, Lees A, Rocha JF, et al. Opicapone as an adjunct to levodopa in patients with Parkinson disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016;15(2):154-165
- [4]Muller T. Catechol-O-methyltransferase inhibitors in Parkinson disease. Drugs. 2015;75(2):157-174
- [5]Tanner CM, Ostrem JL. Parkinson disease. N Engl J Med. 2024;391(5):442-452
Share this article